SCHEMBL30810784

SCHEMBL30810784

CC(C)(C)OC(=O)Nc1c(Cl)cc(Br)c(F)c1[N+](=O)[O-]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.36
▸ PRMT1 Q99873 1/20 0.36
▸ MAPT P10636 5/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ LCK P06239 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ AAK1 Q2M2I8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19776332 1.00 ATR (0.36) ATRPRMT1MAPTSMN1; SMN2ALOX5
SCHEMBL19776245 0.77 KCNH2 (0.35) MAPTKCNH2ALDH1A1COMT
SCHEMBL21395532 0.77 LCK (0.38) ATRMAPTSMN1; SMN2ALOX5NPC1
SCHEMBL28475336 0.76 PRMT1 (0.40) ATRPRMT1MAPTSMN1; SMN2ALOX5
SCHEMBL19782751 0.76 MAPT (0.35) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL30189995 0.76 MAPT (0.35) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL21459919 0.75 KCNH2 (0.34) KCNH2ALDH1A1
SCHEMBL19775905 0.74 ATR (0.41) ATRMAPTSMN1; SMN2ALOX5NPC1
SCHEMBL19776329 0.74 PGK1 (0.40) MAPTSMN1; SMN2NPC1RAB9AKCNH2
SCHEMBL19782960 0.73 MAPT (0.33) MAPTRAB9AKCNH2ALDH1A1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 — — US disclosed
US-20240309019-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-09-19 — — US disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
US-11932658-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 ATR 2659/4885PRMT1 1053/4885MAPT 1155/4885
US-11932658-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, PARP14, F2R ATR 1984/4885PRMT1 711/4885MAPT 1895/4885
US-20240309019-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS F2RL3, PARP14, F2R ATR 2017/4885PRMT1 706/4885MAPT 1726/4885
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, F2R, PF4 ATR 2925/4885PRMT1 513/4885MAPT 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback